tradingkey.logo
tradingkey.logo
Pesquisar

ARS Pharmaceuticals Inc

SPRY
Adicionar à lista de desejos
8.560USD
+0.620+7.81%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
850.01MValor de mercado
PerdaP/L TTM

Mais detalhes de ARS Pharmaceuticals Inc Empresa

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Informações de ARS Pharmaceuticals Inc

Código da empresaSPRY
Nome da EmpresaARS Pharmaceuticals Inc
Data de listagemDec 04, 2020
CEOLowenthal (Richard E)
Número de funcionários155
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 04
Endereço11682 El Camino Real, Suite 300
CidadeSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Telefone18587719307
Sitehttps://ars-pharma.com/
Código da empresaSPRY
Data de listagemDec 04, 2020
CEOLowenthal (Richard E)

Executivos da empresa ARS Pharmaceuticals Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de ARS Pharmaceuticals Inc?

Os cinco principais acionistas de ARS Pharmaceuticals Inc são: Mr. Richard E. Lowenthal

Quantas instituições possuem ações da ARS Pharmaceuticals Inc (SPRY)?

Em 2026Q1, 412 instituições possuíam ações da ARS Pharmaceuticals Inc, com valor de mercado aproximado de 96.79M, representando 97.47% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -8902286.00.